<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00567021</url>
  </required_header>
  <id_info>
    <org_study_id>1312004007</org_study_id>
    <secondary_id>German PMS trial no.7</secondary_id>
    <nct_id>NCT00567021</nct_id>
  </id_info>
  <brief_title>German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms</brief_title>
  <official_title>German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This PMS study had the objective to evaluate under ordinary medical care conditions the
      efficacy and tolerability of esomeprazole in patients who where treated by general
      practitioners and internists.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To gain further insight into the efficacy of esomeprazole under ordinary medical care conditions in consideration of diagnosis and type of NSAID therapy (if administered).</measure>
    <time_frame>By estimating the proportion of treated subjects without any gastrointestinal symptoms at the end of the observational period 2. by assessing the change in intensity of gastrointestinal symptoms.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To get further insight into the details of the use, dosage scheme and duration of treatment with esomeprazole in this population</measure>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">67130</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>patients with GERD or NSAID-related ulcers</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        PC and internist
      </textblock>
    </study_pop>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with GERD, or NSAID related ulcers, who need treatment with esomeprazole.

        Exclusion Criteria:

          -  Limitations; possible risks; warnings; contraindications mentioned in the SPC.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai Richter, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Medical Department</affiliation>
  </overall_official>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2007</study_first_submitted>
  <study_first_submitted_qc>December 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2007</study_first_posted>
  <last_update_submitted>January 28, 2008</last_update_submitted>
  <last_update_submitted_qc>January 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Kai Ritcher</name_title>
    <organization>AstraZeneca Germany</organization>
  </responsible_party>
  <keyword>reflux</keyword>
  <keyword>NSAR treatment</keyword>
  <keyword>Patients with reflux symptoms or gastrointestinal symptoms after NSAR Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

